You can have the most promising product, the strongest launch plan, and the best intentions—but if execution fails, none of it matters.
In biopharma, where stakes are high and timelines are tight, successful launches are rarely the result of last-minute heroics. They’re the product of rigorous preparation, real-time visibility, and a willingness to surface issues before they become problems. That’s where Launch Readiness Reviews (LRRs) come in.
While often misunderstood or treated as status meetings, LRRs—when done right—are a critical de-risking mechanism that separates high-performing launch teams from those constantly reacting to fire drills. They help companies shift from activity to accountability—and from confidence to proof.
Launch Readiness Reviews are structured, formal, cross-functional check points conducted throughout the pre-launch phase—typically at 18-24 months, 6-12months, and 3-6 months before approval or commercial availability. Their purpose is to assess whether all aspects of the launch are considered and aligned for success. While each company should set its own standard for what to include in an LRR, at a minimum, the cross-functional questions included in this infographic should be included for discussion.
LRRs are designed to do more than review milestones. Effective LRRs are decision accelerators. They help teams:
When done right, LRRs become the connective tissue between strategy and execution. They ensure that planning isn’t happening in silos and that critical gaps don’t hide behind functional optimism. When implemented strategically, LRRs become an early warning system and alignment engine, helping teams shift from reactive to proactive.
Even the most experienced teams are prone to blind spots. That’s where the structured cadence of LRRs can serve as a pressure-test for assumptions and timelines.
Some of the most common issues surfaced through LRRs include:
A well-run LRR doesn’t just diagnose these issues. It assigns ownership, timelines, and accountability for resolving them. More importantly, it brings leaders into alignment about the real state of readiness. By identifying these risks at the right time, companies can avoid high-cost course corrections in the final stretch—and ensure all teams are calibrated for success.
To move beyond status updates, LRRs must be built on structure, transparency, and trust. They should be seen not as reporting exercises, but as operational strategy checkpoints. Think of them like a pit-stop during a race—a time to make sure that the launch is fully keyed to its highest potential.
When planning for the LRR meetings, high-performing launch organizations implement the following:
Beyond operational benefits, LRRs shape how teams think, lead, and collaborate during a launch.
They:
When LRRs are taken seriously, they send a clear cultural signal:
“We don’t wait for things to break—we solve them before they do.”
In short, LRRs move teams out of “update mode” and into a mindset of shared ownership and operational excellence.
What makes LRRs truly valuable isn’t the meeting—it’s the movement they create. They give teams a way to convert strategic planning into confident execution by continuously validating whether the launch is truly on track. Most teams believe they’re ready—until the gaps appear. And by then, it’s often too late to fix them without consequence. LRRs ensure readiness is real. By turning gaps into action, surfacing risks early, and aligning teams around shared milestones, LRRs bridge the space between planning and performance.
At Arya Consulting Partners, we help clients design and facilitate LRRs that drive action, not just alignment. We bring a disciplined approach, deep industry benchmarks, and the tools to manage readiness with clarity and urgency. We help you anticipate risk, align stakeholders, and maintain launch momentum from day one to day done.
Contact us at Launch@AryaCP.com to learn how Arya can help you implement a high-impact Launch Readiness Review process that drives visibility, ownership and flawless execution
A global pharmaceutical company sought a strategic plan to guide its CAR cell therapy program, exploring both CAR-T and CAR-NK platforms. Arya facilitated working sessions, conducted primary research, and validated insights to develop a go-to-market roadmap aligned with leadership goals.
Read More
In biopharma, getting a product approved is just one milestone—getting it adopted is the real win. And adoption doesn’t happen in isolation. It requires the trust, belief, and support of a diverse set of stakeholders: payers, providers, patients, and caregivers.
Yet, far too often, stakeholder engagement remains underdeveloped or disconnected. Commercial teams focus on messaging to physicians. Market Access teams work on payer value decks. Medical Affairs builds KOL relationships. But rarely is there a coordinated engagement strategy that aligns messages, timing, and touch points across the entire ecosystem.
The most successful launches approach stakeholder engagement as an integrated, cross-functional priority—not a late-stage communication exercise.
Get expert analysis, industry trends, and exclusive updates delivered straight to your inbox. Stay ahead of the curve with valuable insights that drive success.
